Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Both the companies intend to facilitate faster clinical trial enrollment and provide patients with access to novel medications
He has over two decades of leadership experience as an innovative strategic planner in finance diligence
The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
The partnership will capitalize on the combined capabilities of the two organizations
The appointment is effective from May 01, 2023 for five years
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Subscribe To Our Newsletter & Stay Updated
